Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) has been included in the Financial Times (FT) 1000 report, a list of the companies in 31 European countries that have achieved the highest percentage growth in revenues between 2013 and 2016. We have asked Donato Bonifazi, CEO at CVBF, about the future perspectives and projects for CVBF: “CVBF focuses its main activities in three areas clinical research, innovation and advocacy. Currently the aims are to strengthen our expertise in the clinical research area and at the same time to promote an innovation pipeline “from bench to bedside”, for a quick translation of the results of research for the benefit of patients, mainly in the area of paediatric and rare diseases”.
In particular, which will be the main challenge foreseen in the CVBF future landscape? “Since CVBF most important field of activity is paediatric research, we are working to design the future European Paediatric Translational Research Infrastructure entirely dedicate to paediatric research and including paediatric medicines development models that integrate technology-driven aspects in several different scientific domains: Drug Discovery and Early Development Phases, Preclinical Studies, Paediatric Biomarkers, Developmental Pharmacology, Paediatric Medicines Formulations and Medical Devices.”
Which are the CVBF core competencies to play a leading role in the Italian and European scenarios? “The Clinical Research Area is composed of skilled professionals able to perform all the CRO activities, from monitoring to quality assurance, from pharmacovigilance to biostatistics. The promotion of training and education within CVBF and towards researchers, regulators and patients, is key to guarantee qualified experts, staying always on the ball and able to follow the global transformations in a changing environment.”